Gummy versus capsule prenatal supplements for women in their second trimester.
Official title: Evaluating the Impact of Perelel Prenatal on Biomarkers in Healthy Pregnant Women.
Run by Perelel Inc. · NCT07226414 · Data updated 2026-11-12
This will test whether taking a daily capsule or a daily gummy prenatal for 12 weeks changes blood iron levels in women in their second trimester of pregnancy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 21 Years to 40 Years |
| Sex | Women only |
| Enrollment | 40 (estimated) |
| Sponsor | Perelel Inc. Industry-sponsored |
| Locations | 1 site (Chicago, Illinois) |
| Status | Recruiting |
| Started | December 1, 2025 |
| Main results expected | September 2026 |
| Study ends | November 2026 |
| Registry record updated | December 18, 2025 |
| Trial ID | NCT07226414 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy pregnant women aged 21–40 in their second trimester (14–19 weeks) who can give informed consent and are willing to take a daily prenatal supplement for 12 weeks.
✕Probably not a fit
Women with severe nausea or vomiting, inability to tolerate oral supplements, hypersensitivity to the product ingredients, or significant coexisting health conditions are unlikely to benefit from this comparison.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will have healthy pregnant women in their second trimester take either a Prenatal Capsule or a Prenatal Gummy every day for 12 weeks and compare outcomes between the two groups. Serum iron will be measured at baseline and again after the 12-week intervention to determine any differences. Eligible participants are 21–40 years old with a gestational age of 14–19 weeks and must be willing and able to take the assigned product daily. Participants with severe nausea/vomiting in the first trimester, inability to tolerate oral supplements, hypersensitivity to study product ingredients, or significant coexisting health conditions are excluded.
Why it matters
Potential benefit: If successful, this could help pregnant women and clinicians choose whether a capsule or a gummy better maintains blood iron during the second trimester.
How similar studies have gone: Prior research on iron absorption from different supplement formulations has shown mixed results, and direct comparisons of gummy versus capsule prenatal products for serum iron are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Be able to give written informed consent. * Healthy pregnant women between 21- 40 years of age (inclusive). * Pregnant women in the second trimester of pregnancy (gestational age of 14-19 weeks). * Willing to consume the Study Product daily for the duration of the study. Exclusion Criteria: * History of drug or alcohol abuse * Is hypersensitive to any of the contents of the study product, that would preclude intake of the study products. * Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk, or would confound the interpretation of the study results as judged by the investigator on the basis of medical history. * Severe nausea and vomiting in the first trimester, including hyperemesis gravidarum (HG) * Inability to tolerate oral supplement intake due to gastrointestinal symptoms during the first trimester of pregnancy * Prior Pregnancy Complications (gestational diabetes (GD), HG, or pre-eclampsia, NTDs (Neural Tube Defects)) * Current pregnancy complications (GD, Iron Deficiency Anemia) * Hypertension * Diabetes mellitus * Cardiovascular disease * Class II/III obesity (defined as BMI ≥35.0 Kg/m2) * Malabsorption syndromes (e.g., celiac disease, inflammatory bowel disease) * Severe anemia or iron overload disorders * Thyroid disorders * Current or recent (in the past 12 weeks prior to Visit 1) use of a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results, as judged by the investigator. Prohibited medications include: Medications that contain fat-soluble vitamins A, E, or K in high doses \- Current or recent (in the past 12 weeks prior to Visit 1) use of prohibited nutritional or non-nutritional supplements that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator.
Where it's running
-
Atlantia Clinical Trials, Chicago
Chicago, Illinois, United States Recruiting
Study contacts
- Study coordinator: Dr. Stacey Boetto, DNP, FNP-C Clinical Research Investigator
- Email: sboetto@atlantiatrials.com
- Phone: 312-535 -9440
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pregnant Women Living with HIV on Bictegravir/Emtricitabine/Tenofovir Alafenamide
This study looks at how B/F/TAF is used in pregnant women with HIV and whether it helps maintain viral suppression from before conception through delivery.
-
Pelvic Floor Training and a Modified Lumbopelvic Belt for Symphysis Pubis Pain in Pregnancy
This study tests whether pelvic floor muscle training plus a modified lumbopelvic belt can reduce pain and improve function for pregnant women with symphysis pubis pain.
-
Effective Communication in VBAC Counseling
This study tests how clearly doctors and midwives explain VBAC options during prenatal visits and whether patients feel understood.
-
Innovative Multidisciplinary and Virtual Care for IBD in Pregnancy
This study tests a dedicated IBD pregnancy care model, including a new virtual approach, to see if it improves access and quality of care for pregnant people with Crohn's disease or ulcerative colitis.
-
Compare spinal-epidural versus general anesthesia for babies after cesarean delivery
This trial tests whether the type of anesthesia used for cesarean delivery affects newborn hearing in babies.
-
Pregnant women weight-management support via an app and care model
Aims to try a smartphone-based weight-management program plus professional support for pregnant women to see if it helps manage gestational weight and promote healthy behaviors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.